Status:
COMPLETED
The Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment Experienced Patients
Lead Sponsor:
Thomas Jefferson University
Collaborating Sponsors:
University of Maryland, College Park
Indiana University Health
Conditions:
HIV/AIDS
Eligibility:
All Genders
18+ years
Brief Summary
This study will assess changes in the incidence and severity of drug interactions before and after switching antiretroviral therapy to bictegravir/emtricitabine/tenofovir alafenamide-based regimens in...
Detailed Description
Simple, safe and effective antiretroviral therapy (ART) can provide optimal treatment outcomes for people living with HIV infection (PLWH) \[1\]. Increasingly complex and poorly tolerated regimens, on...
Eligibility Criteria
Inclusion
- HIV diagnosis
- 18 years of age or older
- Receiving ART for at least 3 months
- ART is switched to bictegravir/emtricitabine/tenofovir alafenamide between 2/7/2018 and 3/30/2019
- Patient is receiving at least one chronic or as needed non-ART medication at the time of the switch
Exclusion
- \-
Key Trial Info
Start Date :
September 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 5 2020
Estimated Enrollment :
411 Patients enrolled
Trial Details
Trial ID
NCT03789968
Start Date
September 1 2019
End Date
October 5 2020
Last Update
October 8 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19107